Evidence map›Paper›PMID 33272192›Full record

ArticleBMC infectious diseases2020

Survey on neutralizing antibodies against Zika virus eighteen months post-outbreak in two southern Thailand communities.

Theerut Densathaporn, Rassamee Sangthong, Monvaris Sakolnapa, Smonrapat Surasombatpattana, Marisa Kemapunmanus, Promsin Masrinoul, Sutee Yoksan, Edward B McNeil, Virasakdi Chongsuvivatwong

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Theerut DensathapornEpidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hatyai, 90110, Thailand.
Rassamee SangthongImmunology and Virology Unit, Department of Pathology, Faculty of Medicine, Prince of Songkla University, Hatyai, 90110, Thailand.
Monvaris SakolnapaEpidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hatyai, 90110, Thailand.
Smonrapat SurasombatpattanaImmunology and Virology Unit, Department of Pathology, Faculty of Medicine, Prince of Songkla University, Hatyai, 90110, Thailand.
Marisa KemapunmanusImmunology and Virology Unit, Department of Pathology, Faculty of Medicine, Prince of Songkla University, Hatyai, 90110, Thailand.
Promsin MasrinoulCenter for Vaccine Development, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, 73170, Thailand.
Sutee YoksanCenter for Vaccine Development, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, 73170, Thailand.
Edward B McNeilEpidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hatyai, 90110, Thailand.
Virasakdi ChongsuvivatwongEpidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hatyai, 90110, Thailand. cvirasak@medicine.psu.ac.th.ORCID http://orcid.org/0000-0002-9850-4463
Prince of Songkla University · THMahidol University · TH

Funding

National Foundation for Science and Technology Development (TH) FDA-C0-2561-5958-TH
6 · The paper itself

Abstract

backgroundIn 2016 and 2017, Zika virus (ZIKV) infection outbreaks occurred in two communities in southern Thailand. This re-immerging infection can widely spread by mosquito bites and cause serious complications in a central nervous system among children born to infected mothers. Thus, they should be protected. This study aims to (1) To determine the prevalence of neutralizing ZIKV antibodies in the post-outbreak areas among the general population and pregnancy women residing at various distances from the houses of the nearest index patients; (2) To examine the cross-neutralizing capacity of antibodies against ZIKV on other flaviviruses commonly found in the study areas; (3) To identify factors associated with the presence of neutralizing ZIKV antibodies.

methodsThe two post-outbreak communities were visited at 18 months after the outbreaks. We enrolled (1) 18 confirmed ZIKV infected (index) cases, (2) sample of 554 neighbors in the outbreak areas who lived at various distances from the index patients' houses, (3) 190 residents of non-outbreak areas, and (4) all pregnant women regardless of gestational age residing in the study areas (n = 805). All serum specimens underwent the plaque reduction neutralization test (PRNT). Ten randomly selected ZIKV seropositive and ten randomly selected seronegative specimens were tested for dengue virus serotypes 1-4 (DENV1-4) and Japanese encephalitis virus (JEV) antibodies using PRNT90. Serum titer above 1:10 was considered positive. Multiple logistic regression was used to assess factors associated with seropositivity.

resultsOut of all 18 index cases, 9 remained seropositive. The seroprevalence (95% CI) in the two outbreak areas were 43.7% (35.9-51.6%) and 29.7% (23.3-36.0%) in general population, and 24.3% (20.1-28.8%) and 12.8% (9.7-16.5%) in pregnant women. Multivariate analysis showed that seropositivity was independent of the distance gradient from the index's houses. However, being elderly was associated with seropositivity. DENV1-4 and JEV neutralizing antibodies were present in most ZIKV-positive and negative subsamples.

conclusionProtective herd immunity for ZIKV infection is inadequate, especially among pregnant women in the two post-outbreak areas in southern Thailand.

Indexed as

Disease OutbreaksSurveys and QuestionnairesAdolescentAdultAntibodies, NeutralizingAntibodies, ViralCross ReactionsCross-Sectional StudiesDengueDengue VirusFemaleHumansMaleMiddle AgedNeutralization TestsPregnancyAntibodies, NeutralizingAntibodies, ViralCross-protectionSeroprevalence surveyZika virus

Identifiers

PMID33272192
PMCPMC7711253
OpenAlexW3098057676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.